It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Related articles
Ben Whishaw lights up the Croisette as he joins his co
Ben Whishaw was all smiles at the world premiere of Limonov: The Ballad at the 77th annual Cannes Fi2024-05-21People Enjoy Chinese Lunar New Year Holiday Across China
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Ningbo Holds Series of Activities to Enrich Night Life of Citizens, Tourists
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21- (Xinhua) 16:00, January 04, 2024BEIJING, Jan. 4 (Xinhua) -- The Asian Football Confederation (AFC) h2024-05-21
'Constantly learning' Imanaga off to impressive start with the Chicago Cubs
CHICAGO (AP) — The road for Shota Imanaga from Japan to the major leagues included at least one shar2024-05-21Tea Industry Cultivated to Boost Local Farmers' Income in SW China
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment